New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review
Background: New-onset sarcoidosis has been previously described in three case reports in patients affected by rheumatoid arthritis treated with tocilizumab (TCZ). The existence of a cause–effect mechanism between the biological treatment and the onset of the illness is still being debated. Patient c...
Main Authors: | Rosaria Del Giorno, Alfonso Iodice, Cristina Mangas, Luca Gabutti |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-04-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X19841796 |
Similar Items
-
Design of the Tocilizumab in Giant Cell Arteritis Trial
by: Sebastian H. Unizony, et al.
Published: (2013-01-01) -
Vision loss in patients with giant cell arteritis treated with tocilizumab
by: Jennifer Amsler, et al.
Published: (2021-03-01) -
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
by: Mollan SP, et al.
Published: (2018-01-01) -
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
by: Sara Gale, et al.
Published: (2019-02-01) -
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
by: Maxime Samson, et al.
Published: (2021-01-01)